Physician profile
Suzanne Mcadams
NPI 1497854889
$6,048.06
in general payments reported to CMS, 2019-2025
45 companies · $776 in 2025
The $776 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,312 · 2020: $824 · 2021: $1,008 · 2022: $935 · 2023: $688 · 2024: $506 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,970.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $617.92 | 2021-2025 | Zeposia |
| Amneal Pharmaceuticals LLC | $531.94 | 2019-2025 | Rytary, Crexont, Lyvispah |
| Sunovion Pharmaceuticals INC. | $500.17 | 2019-2021 | |
| Emd Serono, INC. | $344.98 | 2019-2024 | Mavenclad |
| Ucb, INC. | $289.63 | 2019-2025 | Briviact, Nayzilam |
| Harmony Biosciences LLC | $273.51 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $259.23 | 2022-2025 | Nuplazid |
| Supernus Pharmaceuticals, INC. | $258.03 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $257.31 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $213.01 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $206.60 | 2020-2024 | Austedo Xr |
| Mdd US Operations, LLC | $201.23 | 2019-2022 | |
| Biogen, INC. | $169.32 | 2019-2023 | Vumerity |
| Genentech USA, INC. | $163.70 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $155.68 | 2020-2022 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $145.93 | 2025 | Ponvory, Fanapt |
| Adamas Pharmaceuticals, INC. | $139.72 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $129.24 | 2020-2021 | |
| Abbvie INC. | $126.02 | 2021-2025 | |
| Genzyme Corporation | $120.49 | 2019-2023 | |
| Eisai INC. | $99.22 | 2021-2025 | |
| Hospira, INC. | $69.09 | 2021-2023 | |
| Inspire Medical Systems, INC. | $65.69 | 2023-2025 | Inspire |
| Avadel Cns Pharmaceuticals, LLC | $55.40 | 2023-2025 | Lumryz |
| Astrazeneca Pharmaceuticals LP | $54.84 | 2021-2024 | Wainua |
| Sk Life Science, INC. | $54.65 | 2025 | |
| Grifols USA, LLC | $52.67 | 2021-2023 | Gamunex-C |
| Lundbeck LLC | $52.52 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $47.03 | 2023-2025 | Rexulti, Nuedexta |
| Medtronic, INC. | $41.82 | 2024 | Intellis Adaptivestim |
| Tanabe Pharma America, INC. | $41.00 | 2022-2024 | |
| Pfizer INC. | $31.87 | 2024-2025 | |
| Argenx US, INC. | $31.49 | 2025 | Vyvgart Hytrulo |
| Akcea Therapeutics, INC. | $29.74 | 2020 | |
| Allergan, INC. | $29.56 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $29.27 | 2020-2021 | |
| Amgen INC. | $27.44 | 2024 | Aimovig |
| Mallinckrodt Hospital Products INC. | $22.13 | 2021 | |
| Novo Nordisk INC | $19.63 | 2023 | Wegovy |
| Csl Behring | $19.23 | 2025 | Hizentra |
| Acorda Therapeutics, INC | $17.15 | 2022 | |
| Kyowa Kirin, INC. | $15.97 | 2024 | Nourianz |
| Adlon Therapeutics L.P. | $12.82 | 2019 | |
| Assertio Therapeutics, INC. | $12.56 | 2019 | |
| Ge Healthcare | $11.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Mcadams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.